Although a fraction of MBM exhibits immune cell subset enrichment and interferon response signatures and responds to ICi therapy, MET-expressing brain metastatic melanoma cells may benefit from HGF released by stromal cells to drive progression. This evidence concerns the gene MET and metastatic melanoma.